Provided by Tiger Trade Technology Pte. Ltd.

Anaptysbio Inc

55.39
-2.0100-3.50%
Post-market: 55.390.00000.00%18:57 EDT
Volume:957.55K
Turnover:53.44M
Market Cap:1.59B
PE:-120.38
High:58.98
Open:57.06
Low:54.53
Close:57.40
52wk High:68.39
52wk Low:15.40
Shares:28.75M
Float Shares:17.26M
Volume Ratio:1.89
T/O Rate:5.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4601
EPS(LYR):-0.4601
ROE:-24.49%
ROA:7.06%
PB:42.79
PE(LYR):-120.38

Loading ...

AnaptysBio Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 24, 2025

BUZZ-U.S. STOCKS ON THE MOVE-IES Holding, Eli Lilly, Alphabet

Reuters
·
Nov 22, 2025

Sector Update: Health Care Stocks Rise Pre-Bell Friday

MT Newswires Live
·
Nov 21, 2025

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday on Reignited Rate Cut Hopes

MT Newswires Live
·
Nov 21, 2025

BUZZ-AnaptysBio tumbles after latest legal battle over cancer drug

Reuters
·
Nov 21, 2025

Top Premarket Decliners

MT Newswires Live
·
Nov 21, 2025

AnaptysBio initiates litigation against GSK subsidiary Tesaro

TIPRANKS
·
Nov 21, 2025

AnaptysBio announces $100M share repurchase program

TIPRANKS
·
Nov 21, 2025

AnaptysBio Files Complaint Alleging GSK's Tesaro Breached Jemperli Collaboration Deal

MT Newswires Live
·
Nov 21, 2025

AnaptysBio Launches $100 Million Share Buyback Program

MT Newswires Live
·
Nov 21, 2025

Anaptys Announces $100 Million Stock Repurchase Plan

THOMSON REUTERS
·
Nov 21, 2025

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

THOMSON REUTERS
·
Nov 21, 2025

GSK Subsidiary TESARO Sues AnaptysBio Over Jemperli License Dispute

Reuters
·
Nov 21, 2025

GSK: Tesaro, a GSK Subsidiary, Initiates Litigation Against AnaptysBio, Inc

THOMSON REUTERS
·
Nov 21, 2025

GSK: Breach Entitles Tesaro to Terminate Current License Agreement, Obtain a Perpetual and Irrevocable License to Dostarlimab

THOMSON REUTERS
·
Nov 21, 2025

GSK: Breach Entitles to Reduce Royalties and Milestone Payments Due by Tesaro to AnaptysBio by 50%

THOMSON REUTERS
·
Nov 21, 2025

GSK: Recent Conduct by AnaptysBio Is in Material Breach of Existing License Agreement With Tesaro Regarding Oncology Treatment Jemperli

THOMSON REUTERS
·
Nov 21, 2025

GSK-Started Litigation After AnaptysBio's Allegations That Tesaro Has Not Fulfilled Certain Requirements of License Agreement Entered in March 2014

THOMSON REUTERS
·
Nov 21, 2025

GSK: GSK and Tesaro Are Firmly of View That These Allegations Are Entirely "Without Merit"

THOMSON REUTERS
·
Nov 21, 2025

AnaptysBio (ANAB): Evaluating Valuation After Phase 2 Ulcerative Colitis Trial Discontinuation and Cost Savings

Simply Wall St.
·
Nov 20, 2025